---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-100065"
form_type: "8-K/A"
ticker: "RKDA"
cik: "0001469443"
company_name: "Arcadia Biosciences, Inc."
filed_at: "2024-08-23T23:59:59+00:00"
generated_at: "2026-05-31T07:49:42.312381+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Arcadia Biosciences discloses CEO/CFO compensation: $260k/$212k salary, stock options at $2.71

## Summary
- CEO Thomas Schaefer base salary $260k/yr; 2024 target bonus 50% as CEO, 40% as CFO prorated.
- CFO Mark Kawakami base salary $212,063/yr; 2024 target bonus 30% as CFO, 20% as VP Finance prorated.
- Each granted options to buy 20,000 shares at $2.71, vesting over 4 years (25% one-year cliff, 36 monthly).
- Schaefer and Kawakami receive 6-month severance (non-CIC) or 12-month plus full equity vest (CIC).
- Agreements expire third anniversary of July 5, 2024; at-will employment confirmed.

## SEC filing metadata
- accession: 0000950170-24-100065
- form_type: 8-K/A
- ticker: RKDA
- cik: 0001469443
- company_name: Arcadia Biosciences, Inc.
- filed_at: 2024-08-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/0000950170-24-100065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1469443/000095017024100065/rkda-20240702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-100065
- JSON: https://secwatch.observer/filing/0000950170-24-100065.json
- Plain text: https://secwatch.observer/filing/0000950170-24-100065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.